A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | MicrobiomeTrials
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
CompletedPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-09-06Est. Completion: 2025-04-25
Enrollment target: 303 participants
Locations
Accel Clinical Sites Network - Cahaba Medical Care, Birmingham, Alabama, United States
Noble Clinical Research, Tucson, Arizona, United States
Cedars-Sinai Medical Center/Carbon Health, Beverly Hills, California, United States
Acclaim Clinical Research, San Diego, California, United States
Multi-Specialty Research Associates, Inc., Lake City, Florida, United States
Suncoast Research Associates, LLC, Miami, Florida, United States
Johnson County Clin-Trials (JCCT), Lenexa, Kansas, United States
Alliance for Multispecialty Research, LLC, Newton, Kansas, United States
Research Works, New Orleans, Louisiana, United States
Fenway Health, Boston, Massachusetts, United States
DM Clinical Research, Southfield, Michigan, United States
Velocity Clinical Research, Grand Island, Nebraska, United States
Velocity Clinical Research, Norfolk, Nebraska, United States
Rochester Clinical Research, Rochester, New York, United States
M3 Wake Research, Inc., Raleigh, North Carolina, United States
Velocity Clinical Research Cleveland, Beachwood, Ohio, United States
Other microbiome trials you might be interested in